Seres Therapeutics Inc. (Nasdaq: MCRB) reported disappointing results from a Phase 2 study of SER-109 to treat multiply recurrent Clostridium difficult infection sending the stock price plummeting $24.83 to close at $10.94.
Disappointing study results for Seres Therapeutics
July 29, 2016 at 17:53 PM EDT
